Coronado Biosciences Given “Outperform” Rating at Wedbush (CNDO)
Coronado Biosciences (NASDAQ:CNDO)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a note issued to investors on Thursday. They currently have a $13.00 price objective on the stock.
Shares of Coronado Biosciences (NASDAQ:CNDO) traded down 0.56% on Thursday, hitting $1.78. The stock had a trading volume of 82,669 shares. Coronado Biosciences has a 52 week low of $1.25 and a 52 week high of $10.20. The stock has a 50-day moving average of $1.75 and a 200-day moving average of $2.14. The company’s market cap is $78.9 million.
Coronado Biosciences (NASDAQ:CNDO) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.21) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.20) by $0.01. Analysts expect that Coronado Biosciences will post $-0.75 EPS for the current fiscal year.
Coronado Biosciences, Inc is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.